Skip to main content

Advertisement

SpringerLink
Log in

Diagnosis of malignant glioma: role of neuropathology

  • Invited Manuscript
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Burger PC, Scheithauer BW, Lee RR et al (1997) An interdisciplinary approach to avoid the overtreatment of patients with central nervous system lesions. Cancer 80:2040–2046

    Article  PubMed  CAS  Google Scholar 

  2. Burger PC, Nelson JS, Boyko OB (1998) Diagnostic synergy in radiology and surgical neuropathology: neuroimaging techniques and general interpretive guidelines. Arch Pathol Lab Med 122:609–619

    PubMed  CAS  Google Scholar 

  3. Burger PC, Nelson JS, Boyko OB (1998) Diagnostic synergy in radiology and surgical neuropathology: radiographic findings of specific pathologic entities. Arch Pathol Lab Med 122:620–632

    PubMed  CAS  Google Scholar 

  4. Burger PC, Scheithauer BW, Vogel FS (2002) Surgical pathology of the nervous system and its coverings. Churchill Livingstone, New York

    Google Scholar 

  5. Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon

    Google Scholar 

  6. Greenfield JG, Graham DI, Lantos PL (2002) Greenfield’s neuropathology. Arnold, London

    Google Scholar 

  7. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO classification of tumours of the central nervous system. International Agency for Research, Lyon

    Google Scholar 

  8. McLendon RE, Rosenblum MK, Bigner DD (2006) Russel & Rubinstein’s pathology of tumors of the nervous system. Hodder Arnold, London

    Google Scholar 

  9. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184

    PubMed  CAS  Google Scholar 

  10. Riley RD, Ridley G, Williams K et al (2007) Prognosis research: toward evidence-based results and a Cochrane methods group. J Clin Epidemiol 60:863–865, author reply 865–866

    Article  PubMed  Google Scholar 

  11. Altman DG, Riley RD (2005) Primer: an evidence-based approach to prognostic markers. Nat Clin Pract Oncol 2:466–472

    Article  PubMed  Google Scholar 

  12. Walters BC (1998) Clinical practice parameter development in neurosurgery. In: Bean J (ed) Neurosurgery in transition: the socioeconomic transformation of neurological surgery. Williams and Wilkins, Baltimore, pp 99–111

    Google Scholar 

  13. Lai R, Chu R, Fraumeni M et al (2006) Quality of randomized controlled trials reporting in the primary treatment of brain tumors. J Clin Oncol 24:1136–1144

    Article  PubMed  Google Scholar 

  14. Moher D, Schulz KF, Altman DG (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191–1194

    Article  PubMed  CAS  Google Scholar 

  15. Bullock R, Chesnut RM, Clifton G et al (1996) Guidelines for the management of severe head injury. Brain Trauma Foundation. Eur J Emerg Med 3:109–127

    Article  PubMed  CAS  Google Scholar 

  16. Bigner DD, McLendon RE, Bruner JM (1998) Russell & Rubinstein’s pathology of tumors of the nervous system. Arnold, London

    Google Scholar 

  17. Burger PC, Scheithauer BW (1994) Tumors of the central nervous system. Armed Forces Institute of Pathology, Washington, DC

  18. Ringertz N (1950) Grading of gliomas. Acta Pathol Microbiol Scand 27:51–64

    PubMed  CAS  Google Scholar 

  19. Kernohan JW, Sayre GP, Armed Forces Institute of Pathology (U.S.) (1952) Tumors of the central nervous system. Armed Forces Institute of Pathology; sold by American Registry of Pathology, Washington, DC

  20. Zülch KJ, Organization WorldHealth (1979) Histological typing of tumours of the central nervous system. World Health Organization, Geneva

    Google Scholar 

  21. Daumas-Duport C, Scheithauer B, O’Fallon J et al (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152–2165

    Article  PubMed  CAS  Google Scholar 

  22. Revesz T, Scaravilli F, Coutinho L et al (1993) Reliability of histological diagnosis including grading in gliomas biopsied by image-guided stereotactic technique. Brain 116(Pt 4):781–793

    Article  PubMed  Google Scholar 

  23. Gupta M, Djalilvand A, Brat DJ (2005) Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am J Clin Pathol 124:755–768

    Article  PubMed  CAS  Google Scholar 

  24. Giannini C, Scheithauer BW, Burger PC et al (1999) Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol 58:46–53

    Article  PubMed  CAS  Google Scholar 

  25. Ashby LS, Shapiro WR (2004) Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults. Curr Neurol Neurosci Rep 4:211–217

    Article  PubMed  Google Scholar 

  26. Coons SW, Pearl DK (1998) Mitosis identification in diffuse gliomas: implications for tumor grading. Cancer 82:1550–1555

    Article  PubMed  CAS  Google Scholar 

  27. Brat DJ, Mapstone TB (2003) Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med 138:659–668

    PubMed  Google Scholar 

  28. Barker FG 2nd, Davis RL, Chang SM et al (1996) Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77:1161–1166

    Article  PubMed  Google Scholar 

  29. Giannini C, Scheithauer BW, Weaver AL et al (2001) Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60:248–262

    PubMed  CAS  Google Scholar 

  30. Mork SJ, Halvorsen TB, Lindegaard KF et al (1986) Oligodendroglioma. Histologic evaluation and prognosis. J Neuropathol Exp Neurol 45:65–78

    Article  PubMed  CAS  Google Scholar 

  31. Burger PC, Rawlings CE, Cox EB et al (1987) Clinicopathologic correlations in the oligodendroglioma. Cancer 59:1345–1352

    Article  PubMed  CAS  Google Scholar 

  32. Miller CR, Dunham CP, Scheithauer BW et al (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24:5419–5426

    Article  PubMed  Google Scholar 

  33. Smith SF, Simpson JM, Brewer JA et al (2006) The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients. J Neurooncol 80:75–82

    Article  PubMed  Google Scholar 

  34. Shaw EG, Scheithauer BW, O’Fallon JR (1997) Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 31:273–278

    Article  PubMed  CAS  Google Scholar 

  35. Shaw EG, Scheithauer BW, O’Fallon JR et al (1994) Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 34:577–582, discussion 582

    Article  PubMed  CAS  Google Scholar 

  36. Donahue B, Scott CB, Nelson JS et al (1997) Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83–02. Int J Radiat Oncol Biol Phys 38:911–914

    PubMed  CAS  Google Scholar 

  37. Coons SW, Johnson PC, Scheithauer BW et al (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393

    Article  PubMed  CAS  Google Scholar 

  38. Mittler MA, Walters BC, Stopa EG (1996) Observer reliability in histological grading of astrocytoma stereotactic biopsies. J Neurosurg 85:1091–1094

    PubMed  CAS  Google Scholar 

  39. Prayson RA, Agamanolis DP, Cohen ML et al (2000) Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. J Neurol Sci 175:33–39

    Article  PubMed  CAS  Google Scholar 

  40. Burger PC, Nelson JS (1997) Stereotactic brain biopsies: specimen preparation and evaluation. Arch Pathol Lab Med 121:477–480

    PubMed  CAS  Google Scholar 

  41. Burger PC, Vogel FS (1978) Frozen section interpretation in surgical neuropathology. II. Intraspinal lesions. Am J Surg Pathol 2:81–95

    PubMed  CAS  Google Scholar 

  42. Martinez AJ, Pollack I, Hall WA et al (1988) Touch preparations in the rapid intraoperative diagnosis of central nervous system lesions. A comparison with frozen sections and paraffin-embedded sections. Mod Pathol 1:378–384

    PubMed  CAS  Google Scholar 

  43. Reyes MG, Homsi MF, McDonald LW et al (1991) Imprints, smears, and frozen sections of brain tumors. Neurosurgery 29:575–579

    Article  PubMed  CAS  Google Scholar 

  44. Colbassani HJ, Nishio S, Sweeney KM et al (1988) CT-assisted stereotactic brain biopsy: value of intraoperative frozen section diagnosis. J Neurol Neurosurg Psychiatry 51:332–341

    PubMed  CAS  Google Scholar 

  45. Brainard JA, Prayson RA, Barnett GH (1997) Frozen section evaluation of stereotactic brain biopsies: diagnostic yield at the stereotactic target position in 188 cases. Arch Pathol Lab Med 121:481–484

    PubMed  CAS  Google Scholar 

  46. Burger PC (1985) Use of cytological preparations in the frozen section diagnosis of central nervous system neoplasia. Am J Surg Pathol 9:344–354

    Article  PubMed  CAS  Google Scholar 

  47. Ironside JW (1994) Update on central nervous system cytopathology. II. Brain smear technique. J Clin Pathol 47:683–688

    Article  PubMed  CAS  Google Scholar 

  48. Gaudin PB, Sherman ME, Brat DJ et al (1997) Accuracy of grading gliomas on CT-guided stereotactic biopsies: a survival analysis. Diagn Cytopathol 17:461–466

    Article  PubMed  CAS  Google Scholar 

  49. Roessler K, Dietrich W, Kitz K (2002) High diagnostic accuracy of cytologic smears of central nervous system tumors. A 15-year experience based on 4, 172 patients. Acta Cytol 46:667–674

    PubMed  Google Scholar 

  50. Firlik KS, Martinez AJ, Lunsford LD (1999) Use of cytological preparations for the intraoperative diagnosis of stereotactically obtained brain biopsies: a 19-year experience and survey of neuropathologists. J Neurosurg 91:454–458

    PubMed  CAS  Google Scholar 

  51. Bleggi-Torres LF, de Noronha L, Schneider Gugelmin E et al (2001) Accuracy of the smear technique in the cytological diagnosis of 650 lesions of the central nervous system. Diagn Cytopathol 24:293–295

    Article  PubMed  CAS  Google Scholar 

  52. Shah AB, Muzumdar GA, Chitale AR et al (1998) Squash preparation and frozen section in intraoperative diagnosis of central nervous system tumors. Acta Cytol 42:1149–1154

    PubMed  CAS  Google Scholar 

  53. Cosgrove M, Fitzgibbons PL, Sherrod A et al (1989) Intermediate filament expression in astrocytic neoplasms. Am J Surg Pathol 13:141–145

    PubMed  CAS  Google Scholar 

  54. Oh D, Prayson RA (1999) Evaluation of epithelial and keratin markers in glioblastoma multiforme: an immunohistochemical study. Arch Pathol Lab Med 123:917–920

    PubMed  CAS  Google Scholar 

  55. Kros JM, Van Eden CG, Stefanko SZ et al (1990) Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas. Cancer 66:1204–1212

    Article  PubMed  CAS  Google Scholar 

  56. Herpers MJ, Budka H (1984) Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma. Acta Neuropathol (Berl) 64:265–272

    Article  CAS  Google Scholar 

  57. Dehghani F, Schachenmayr W, Laun A et al (1998) Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berl) 95:493–504

    Article  CAS  Google Scholar 

  58. Kriho VK, Yang HY, Moskal JR et al (1997) Keratin expression in astrocytomas: an immunofluorescent and biochemical reassessment. Virchows Arch 431:139–147

    Article  PubMed  CAS  Google Scholar 

  59. Cosgrove MM, Rich KA, Kunin SA et al (1993) Keratin intermediate filament expression in astrocytic neoplasms: analysis by immunocytochemistry, western blot, and northern hybridization. Mod Pathol 6:342–347

    PubMed  CAS  Google Scholar 

  60. Nakopoulou L, Kerezoudi E, Thomaides T et al (1990) An immunocytochemical comparison of glial fibrillary acidic protein, S-100p and vimentin in human glial tumors. J Neurooncol 8:33–40

    Article  PubMed  CAS  Google Scholar 

  61. de Wit NJ, van Muijen GN, Ruiter DJ (2004) Immunohistochemistry in melanocytic proliferative lesions. Histopathology 44:517–541

    Article  PubMed  Google Scholar 

  62. Prayson RA (2002) Cell proliferation and tumors of the central nervous system, part II: radiolabeling, cytometric, and immunohistochemical techniques. J Neuropathol Exp Neurol 61:663–672

    PubMed  Google Scholar 

  63. McKeever PE, Ross DA, Strawderman MS et al (1997) A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 56:798–805

    Article  PubMed  CAS  Google Scholar 

  64. Hsu DW, Louis DN, Efird JT et al (1997) Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 56:857–865

    Article  PubMed  CAS  Google Scholar 

  65. Wakimoto H, Aoyagi M, Nakayama T et al (1996) Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 77:373–380

    Article  PubMed  CAS  Google Scholar 

  66. Moskowitz SI, Jin T, Prayson RA (2006) Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol 76:193–200

    Article  PubMed  Google Scholar 

  67. Coons SW, Johnson PC, Pearl DK (1997) The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 41:878–884 discussion 884–875

    Article  PubMed  CAS  Google Scholar 

  68. Marie D, Liu Y, Moore SA et al (2001) Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer 92:2720–2726

    Article  PubMed  CAS  Google Scholar 

  69. Hunter SB, Brat DJ, Olson JJ et al (2003) Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). Int J Oncol 23:857–869

    PubMed  CAS  Google Scholar 

  70. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489

    PubMed  CAS  Google Scholar 

  71. Collins VP (2007) Mechanisms of disease: genetic predictors of response to treatment in brain tumors. Nat Clin Pract Oncol 4:362–374

    Article  PubMed  CAS  Google Scholar 

  72. Smith JS, Perry A, Borell TJ et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645

    PubMed  CAS  Google Scholar 

  73. Perry A, Fuller CE, Banerjee R et al (2003) Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 8:a1–9

    Article  PubMed  CAS  Google Scholar 

  74. Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479

    Article  PubMed  CAS  Google Scholar 

  75. Smith JS, Alderete B, Minn Y et al (1999) Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18:4144–4152

    Article  PubMed  CAS  Google Scholar 

  76. Aldape K, Burger PC, Perry A (2007) Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131:242–251

    PubMed  CAS  Google Scholar 

  77. Reifenberger J, Reifenberger G, Liu L et al (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190

    PubMed  CAS  Google Scholar 

  78. McDonald JM, See SJ, Tremont IW et al (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104:1468–1477

    Article  PubMed  CAS  Google Scholar 

  79. Burger PC, Minn AY, Smith JS et al (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14:842–853

    Article  PubMed  CAS  Google Scholar 

  80. Ueki K, Nishikawa R, Nakazato Y et al (2002) Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 8:196–201

    PubMed  CAS  Google Scholar 

  81. Nigro JM, Takahashi MA, Ginzinger DG et al (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158:1253–1262

    PubMed  CAS  Google Scholar 

  82. Chahlavi A, Kanner A, Peereboom D et al (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:267–273

    Article  PubMed  Google Scholar 

  83. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714

    Article  PubMed  CAS  Google Scholar 

  84. Brat DJ, Seiferheld WF, Perry A et al (2004) Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro-oncol 6:96–103

    Article  PubMed  CAS  Google Scholar 

  85. Schmidt MC, Antweiler S, Urban N et al (2002) Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321–328

    PubMed  CAS  Google Scholar 

  86. Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256

    Article  PubMed  CAS  Google Scholar 

  87. Liu L, Backlund LM, Nilsson BR et al (2005) Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83:917–926

    Article  PubMed  CAS  Google Scholar 

  88. Frederick L, Wang XY, Eley G et al (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387

    PubMed  CAS  Google Scholar 

  89. Wong AJ, Ruppert JM, Bigner SH et al (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965–2969

    Article  PubMed  CAS  Google Scholar 

  90. Olson JJ, Barnett D, Yang J et al (1998) Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 4:215–222

    PubMed  CAS  Google Scholar 

  91. Huncharek M, Kupelnick B (2000) Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 12:107–112

    PubMed  CAS  Google Scholar 

  92. Simmons ML, Lamborn KR, Takahashi M et al (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122–1128

    PubMed  CAS  Google Scholar 

  93. Aldape KD, Ballman K, Furth A et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700–707

    PubMed  CAS  Google Scholar 

  94. Heimberger AB, Hlatky R, Suki D et al (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462–1466

    Article  PubMed  CAS  Google Scholar 

  95. Perry A, Aldape KD, George DH et al (2004) Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 101:2318–2326

    Article  PubMed  Google Scholar 

  96. Burger PC, Pearl DK, Aldape K et al (2001) Small cell architecture–a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 60:1099–1104

    PubMed  CAS  Google Scholar 

  97. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024

    Article  PubMed  CAS  Google Scholar 

  98. Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142

    Article  PubMed  CAS  Google Scholar 

  99. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958–2970

    PubMed  CAS  Google Scholar 

  100. Haas-Kogan DA, Prados MD, Tihan T et al (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880–887

    Article  PubMed  CAS  Google Scholar 

  101. Stommel JM, Kimmelman AC, Ying H et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287–290

    Article  PubMed  CAS  Google Scholar 

  102. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354

    Article  PubMed  CAS  Google Scholar 

  103. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  104. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  PubMed  CAS  Google Scholar 

  105. Mikeska T, Bock C, El-Maarri O et al (2007) Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis. J Mol Diagn 9:368–381

    Article  PubMed  CAS  Google Scholar 

  106. Pollack IF, Hamilton RL, Sobol RW et al (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG–945 Cohort. J Clin Oncol 24:3431–3437

    Article  PubMed  CAS  Google Scholar 

  107. Fruehauf JP, Brem H, Brem S et al (2006) In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 12:4523–4532

    Article  PubMed  CAS  Google Scholar 

  108. Grasbon-Frodl EM, Kreth FW, Ruiter M et al (2007) Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121:2458–2464

    Article  PubMed  CAS  Google Scholar 

  109. Bao S, Wu Q, McLendon RE et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760

    Article  PubMed  CAS  Google Scholar 

  110. Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401

    Article  PubMed  CAS  Google Scholar 

  111. Khwaja FW, Duke-Cohan JS, Brat DJ et al (2006) Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res 12:6331–6336

    Article  PubMed  CAS  Google Scholar 

  112. Khwaja FW, Nolen JD, Mendrinos SE et al (2006) Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 6:6277–6287

    Article  PubMed  CAS  Google Scholar 

  113. Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157–173

    Article  PubMed  CAS  Google Scholar 

  114. Nutt CL, Mani DR, Betensky RA et al (2003) Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602–1607

    PubMed  CAS  Google Scholar 

  115. Pomeroy SL, Tamayo P, Gaasenbeek M et al (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436–442

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We wish to acknowledge Beverly Murphy for her assistance in creating a coherent series of literature searches. Additionally we wish to thank Stephen Haines, MD, Jack Rock, MD, Tom Mikkelson, MD for their review and consultations regarding on this work. The members of the committees express appreciation to the AANS/CNS Joint Guidelines Committee for their review, comments and suggestions. We also thank Linda Phillips for meeting organization and collection of materials and Emily Feinstein for her assistance in editing the material for publication. Additionally we want to acknowledge the unrestricted financial grants provided by Aesculap, Inc., Codman, A Johnson and Johnson, Company., NeoPharm, Inc., Stryker/Leibinger Inc., Schering-Plough, and Guilford Pharmaceuticals for support of the venues in which the experts gathered for development and review of the guidelines.

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Emory University Hospital, G-169, 1364 Clifton Rd. NE, Atlanta, GA, 30322, USA

    Daniel J. Brat

  2. Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH, USA

    Richard A. Prayson

  3. Department of Neurosurgery, University of Iowa College of Medicine, Iowa City, IA, USA

    Timothy C. Ryken

  4. Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA

    Jeffrey J. Olson

Authors
  1. Daniel J. Brat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard A. Prayson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy C. Ryken
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeffrey J. Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Brat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brat, D.J., Prayson, R.A., Ryken, T.C. et al. Diagnosis of malignant glioma: role of neuropathology. J Neurooncol 89, 287–311 (2008). https://doi.org/10.1007/s11060-008-9618-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-008-9618-1

Keywords

Search

Navigation